Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy

•Positive MYC immunostaining is an independent predictor of survival after immunotherapy.•MYC positive and PD-L1 negative cases had shortest overall survival.•MYC copy number gain was not predictive of MYC immunostaining or survival differences.•MYC immunohistochemistry may be of relevance to lung c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2024-09, Vol.195, p.107927, Article 107927
Hauptverfasser: Naso, Julia, Desai, Aakash, Smith, Caleb J., Ashara, Yash P., Yip, Stephen, Lo, Ying-Chun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Positive MYC immunostaining is an independent predictor of survival after immunotherapy.•MYC positive and PD-L1 negative cases had shortest overall survival.•MYC copy number gain was not predictive of MYC immunostaining or survival differences.•MYC immunohistochemistry may be of relevance to lung cancer treatment selection. Accurately predicting which patients diagnosed with non-small cell lung cancer (NSCLC) will respond to immunotherapy remains a clinical challenge. This study aims to determine the associations between MYC immunoreactivity, MYC copy number gain (CNG), driver mutations and survival following immunotherapy treatment, to provide insight into whether clinical MYC assessment may have predictive value. MYC copy number status was determined in 82 patients with NSCLC treated with immunotherapy, and MYC immunohistochemistry (IHC) was performed on 80 of these cases. MYC staining in ≥ 40 % of tumor cells was considered positive. Driver gene alterations, PD-L1 status and survival outcomes were assessed through retrospective chart review. Overall survival (OS) and progression free survival (PFS) were calculated from the date of immunotherapy initiation. Nine (11 %) of 82 cases had MYC CNG and 56 (70 %) of the 80 immunostained cases were positive for MYC. MYC CNG was significantly associated with STK11 mutation (P=0.023), whereas positive MYC IHC was significantly associated with KRAS mutation (P=0.0076) and current/former smoking (P=0.0007). MYC CNG and positive MYC IHC were not significantly associated with each other (P=0.42), or with PD-L1 ≥ 1 % (MYC CNG: P=0.10; MYC IHC: P=0.09). Positive MYC IHC and PD-L1 ≥ 1 % were both significant predictors of OS (MYC: HR 2.7, 95 % CI 1.1–6.4, P=0.026; PD-L1: HR 0.33, 95 % CI 0.15–0.72, P=0.0055). MYC IHC positive/PD-L1 
ISSN:0169-5002
1872-8332
1872-8332
DOI:10.1016/j.lungcan.2024.107927